Navigation Links
Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts
Date:6/15/2009

SAN FRANCISCO, June 15 /PRNewswire-FirstCall/ -- Early results from the second series of trials have demonstrated a 5 log reduction (99.999%) in Pseudomonas aeruginousa and a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus (MRSA). Both of these pathogens are of major concern to medical treatment facilities world wide with the spread of MRSA infection often being referred to as the "silent epidemic". The CDC reported (JAMA 2007) that MRSA alone is now associated with an estimated 19,000 deaths annually in the US. Dr. Michael E. Shannon, Medizone's Director of Medical Affairs commented, "Although the results from our first round of trials were very encouraging, introducing several procedural refinements in this second round resulted in levels of bactericidal action well above what was expected. Indeed, breaking through the 5 log barrier has led us to conclude that with a third technological development still to be introduced in this series of trials, the bactericidal ceiling for our system is now unclear, but well above what we ever expected. Needless to say, we are very excited over these findings and even more convinced that our new technologies will save hundreds of thousands of lives each year world wide. Add to the system's efficacy the fact that it will be safe, extremely cost effective and adaptable to virtually any situation anywhere, leads me to conclude that AsepticSure will have a global reach."

In parallel research recently conducted at BioZone Corporation, Medizone's engineering development partner, it was confirmed the AsepticSure(TM) hospital sterilization system can charge a room of 1,065 cubic feet to our target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns. From a commercial viewpoint, the higher the "kill rate" in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.

Medizone International, Inc. (Pink Sheets: MZEI), is a research and development company engaged in developing its' AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are targeted to commence in the 4th quarter of this year.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Investor Relations 800-953-3350 / web site: www.medizoneint.com

E-mail: operations@medizoneint.com


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.
2. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
3. Medizone Announces a Second Round of Trials Have Begun.
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology: